Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer
- Determine the response rate, progression time, and survival of patients with
platinum-resistant ovarian cancer treated with weekly paclitaxel and gemcitabine.
- Determine the toxic effects of this regimen in these patients.
- Evaluate the toxic effects and safety profile of premedication with steroids with this
regimen in these patients.
OUTLINE: Patients are stratified according to prior treatment with paclitaxel (none or
relapse more than 6 months after paclitaxel versus progressive disease or relapse less than
6 months after paclitaxel).
Patients receive dexamethasone IV, then paclitaxel IV followed by gemcitabine IV, for 3
consecutive weeks on days 1, 8, and 15. Treatment is continued every 4 weeks in the absence
of disease progression or unacceptable toxicity.
All patients are followed until death.
PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study.
Primary Purpose: Treatment
Agustin Garcia, MD
USC/Norris Comprehensive Cancer Center
United States: Federal Government
|USC/Norris Comprehensive Cancer Center and Hospital||Los Angeles, California 90033-0804|